Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.
about
hENT1 expression is predictive of gemcitabine outcome in pancreatic cancer: a systematic reviewSystemic therapies for pancreatic cancer--the role of pharmacogeneticsHoloclone forming cells from pancreatic cancer cells enrich tumor initiating cells and represent a novel model for study of cancer stem cellsAlgorithmic modeling quantifies the complementary contribution of metabolic inhibitions to gemcitabine efficacyGemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cellsTransplanting normal vascular proangiogenic cells to tumor-bearing mice triggers vascular remodeling and reduces hypoxia in tumorsThe O-glycan pathway is associated with in vitro sensitivity to gemcitabine and overall survival from ovarian cancerTherapeutic modalities of squalenoyl nanocomposites in colon cancer: an ongoing search for improved efficacyAdvanced pancreatic cancer: flourishing novel approaches in the era of biological therapy.Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy.The development of orally administrable gemcitabine prodrugs with D-enantiomer amino acids: enhanced membrane permeability and enzymatic stabilityCNT1 expression influences proliferation and chemosensitivity in drug-resistant pancreatic cancer cellsGenexol inhibits primary tumour growth and metastases in gemcitabine-resistant pancreatic ductal adenocarcinomaIn vitro and in vivo anti-tumor activities of a gemcitabine derivative carried by nanoparticles.Modular polymer-caged nanobins as a theranostic platform with enhanced magnetic resonance relaxivity and pH-responsive drug release.Prognostic value of human equilibrative nucleoside transporter1 in pancreatic cancer receiving gemcitabin-based chemotherapy: a meta-analysis.Stearoyl gemcitabine nanoparticles overcome resistance related to the over-expression of ribonucleotide reductase subunit M1.Zidovudine, an anti-viral drug, resensitizes gemcitabine-resistant pancreatic cancer cells to gemcitabine by inhibition of the Akt-GSK3β-Snail pathway.An increase of cytochrome C oxidase mediated disruption of gemcitabine incorporation into DNA in a resistant KB cloneEnhanced subunit interactions with gemcitabine-5'-diphosphate inhibit ribonucleotide reductases.Verapamil inhibits tumor progression of chemotherapy-resistant pancreatic cancer side population cells.Fasting cycles potentiate the efficacy of gemcitabine treatment in in vitro and in vivo pancreatic cancer models.Metastatic pancreatic cancer: are we making progress in treatment?In vitro synergistic cytotoxicity of gemcitabine and pemetrexed and pharmacogenetic evaluation of response to gemcitabine in bladder cancer patients.Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survivalHuman equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancerTreatment of pancreatic cancer: what can we really predict today?Human Equilibrative Nucleoside Transporter 1 (hENT1) in Pancreatic Adenocarcinoma: Towards Individualized Treatment Decisions.The MUC4 mucin mediates gemcitabine resistance of human pancreatic cancer cells via the Concentrative Nucleoside Transporter family.The dipeptide monoester prodrugs of floxuridine and gemcitabine-feasibility of orally administrable nucleoside analogs.Vasohibin 2 reduces chemosensitivity to gemcitabine in pancreatic cancer cells via Jun proto-oncogene dependent transactivation of ribonucleotide reductase regulatory subunit M2.Overcoming nucleoside analog chemoresistance of pancreatic cancer: a therapeutic challenge.Membrane drug transporters and chemoresistance in human pancreatic carcinoma.Drug Loaded Gingival Mesenchymal Stromal Cells (GinPa-MSCs) Inhibit In Vitro Proliferation of Oral Squamous Cell Carcinoma.Graphical Modeling Meets Systems Pharmacology.Harnessing Solute Carrier Transporters for Precision Oncology.Molecular predictors of gemcitabine response in pancreatic cancer.Interdependence of gemcitabine treatment, transporter expression, and resistance in human pancreatic carcinoma cells.Gemcitabine intercellular diffusion mediated by gap junctions: new implications for cancer therapy.Imatinib-resistant CML cells have low ENT activity but maintain sensitivity to gemcitabine.
P2860
Q26862139-CF448311-59D3-4B8E-B13F-1A829BF7C3DEQ27021716-FC0240E3-5606-471F-B01D-48BBDB39E432Q28476426-CE31E04C-8620-4972-B12C-E2B65E426D5FQ28484288-F052AB8A-1C08-4966-B303-52DF154B6EA5Q29937967-4D98A992-84EA-4B7C-9858-5325DE18C7A2Q30499092-54A4C7A1-F3E8-49B0-A019-A80E52BFEC1EQ33597112-F5ACBD9B-310B-4AA2-A565-48F42AE21B96Q33765417-A038A62C-B3C6-4B8C-9307-F211C5B9DB29Q34127857-9BF3A77F-E02F-4067-8FF1-335DC3D1239BQ34177223-6FBAE966-9C47-4DD7-A346-170608D99B79Q34570055-CA017D88-97E7-41AD-B4FB-6B26AD85A568Q34621614-D29EF6EB-A2A2-4D24-A3E9-E77047A16A16Q34625514-AFB850E5-3CF9-494C-9228-577E2DEDB7FBQ34819537-D5B8D4C9-C8A4-4112-8C9C-F30A99F4CCBEQ34988879-D8870F7D-D28F-4C37-B2FB-FF2683DB959FQ35086475-EE2FADA5-D574-4F16-A46D-3B0293478C68Q35610203-EF260C8F-F8B1-4AB7-964C-1F6CF355B2DCQ35674606-EAADB613-6ACE-4B12-B412-A3C5E9EDFFF5Q35945507-64254B0A-7E4B-4943-861C-84DDCA199D84Q35971682-BC1D80E7-16A8-4313-8667-305F095A15E3Q36017448-676F149F-57A8-42F1-A981-3D5A87688152Q36210934-1F7DD53B-9098-4585-A389-539B270DE835Q36469038-3835AA56-E5FE-463F-A176-D549CE902401Q36612195-2FEE3570-3E98-4011-BE80-B09B4D8BC33FQ36747210-1E0FA95E-773E-4C7B-9B6F-009C84C85356Q36775333-7FA38D77-AA67-47AB-82C0-E660B81371B9Q37129815-26D41B9B-B0B4-416A-BDB2-D64CAE955FA7Q37342736-B7D036CB-6FF8-41C6-BA05-27D4A881DEA9Q37605606-65366FA3-C0A0-494E-8F93-5704364196DCQ37617635-11AB571C-2FEA-4CA4-A9B2-5442EDEA28BDQ37713632-77649168-8C41-41C4-BD6D-7F412FC315F3Q37994505-DBA09115-C37C-4F18-A281-9DCB9A33A7ACQ38161328-93CC3322-0F2C-4BE6-9A9F-B5FB8819D253Q38637527-6D6C0A6C-3497-47E5-8B23-850838E8BB6AQ38806208-15F6C3BA-0879-4BD3-BD1D-1505B7C31F50Q39204754-01ED65C2-2D00-4DD9-AF87-97F4CA1410F8Q39250668-C4CD94B0-5EC4-4A7E-B955-72A5F57A65EDQ39658359-3BA7EBB3-AB0E-401F-9629-81E36BF07641Q39694952-D83F05F0-D4A5-436A-9E4C-952BD664D7FDQ39965234-B397F6E2-2033-4959-A74C-EE9D0D9385AA
P2860
Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2',2'-difluorodeoxycytidine- induced cytotoxicity.
description
2003 nî lūn-bûn
@nan
2003 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Nucleoside transporter profile ...... ytidine- induced cytotoxicity.
@ast
Nucleoside transporter profile ...... ytidine- induced cytotoxicity.
@en
Nucleoside transporter profile ...... ytidine- induced cytotoxicity.
@nl
type
label
Nucleoside transporter profile ...... ytidine- induced cytotoxicity.
@ast
Nucleoside transporter profile ...... ytidine- induced cytotoxicity.
@en
Nucleoside transporter profile ...... ytidine- induced cytotoxicity.
@nl
prefLabel
Nucleoside transporter profile ...... ytidine- induced cytotoxicity.
@ast
Nucleoside transporter profile ...... ytidine- induced cytotoxicity.
@en
Nucleoside transporter profile ...... ytidine- induced cytotoxicity.
@nl
P2093
P1476
Nucleoside transporter profile ...... cytidine- induced cytotoxicity
@en
P2093
Adela Mazo
F Javier Casado
José García-Manteiga
Marçal Pastor-Anglada
Míriam Molina-Arcas
P304
P407
P577
2003-10-01T00:00:00Z